Eiger to discontinue hepatitis drug study
12/09/2023 21:12
Sept 12 (Reuters) - Eiger BioPharmaceuticals Inc EIGR.O said on Tuesday it would discontinue a late-stage study testing its experimental drug to treat the most severe form of viral hepatitis. (Reporting by Mariam Sunny in Bengaluru) ((Mariam.ESunny@thomsonreuters.com;))
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview